Developing successful medicines depends on picking the right target and product profile based on the disease biology of your patients.
We enable you to achieve this by identifying causal druggable genes and stratifying patient populations at an unprecedented level of resolution – uncovering patient subgroups with distinct disease etiologies to find new targets for therapeutic intervention.
Access novel targets with extensive data packages, matched to patients with unmet medical needs
Understand the link between dysregulated biological pathways and multiple disease indications
License biomarkers to select patients for clinical trials, and support product launch and market adoption
Our high-resolution patient stratification reveals previously unrecognized disease mechanisms which bring with them new targets for drug discovery and opportunities for first-in-class medicines.
Our patient stratification provides biomarkers for the selection of highly relevant translational disease models, in patient selection for clinical trials, and in the design of companion diagnostics.
To ensure the right targets are selected, we apply proven drug discovery evaluation frameworks, such as the 5Rs criteria for small molecules and extend them to include the selection of targets with the right efficacy potential to minimize late-stage failure risks in downstream clinical trials.
We were the first to successfully stratify ALS patients into clinically relevant subgroups based on their genetic differences and identify novel druggable targets with genetic linkage to the stratified patient subgroups.
Our approach enables a precision medicine in complex chronic diseases – uniquely matching targets to the patient sub-populations that are most likely to benefit.
We integrate all forms of large datasets to rapidly provide links to new areas of biology and potential new therapeutic targets.
And our mechanistic patient stratification biomarkers accurately match new therapies to responders in downstream clinical trials and the clinic.
